Cover: Measuring Patient-Centered Outcomes in the Pfizer-CCTG Trial of Azithromycin vs. Rifabutin vs. Both for the Prevention of HIV-Associated Mycobacterium avium

Measuring Patient-Centered Outcomes in the Pfizer-CCTG Trial of Azithromycin vs. Rifabutin vs. Both for the Prevention of HIV-Associated Mycobacterium avium

Instruments, Methods, Application, and Results

Published 1996

by Samuel A. Bozzette, Sandra H. Berry, Brian C. Wright, David E. Kanouse, Naihua Duan, Carol A. Edwards

Download eBook for Free

FormatFile SizeNotes
PDF file 2.3 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

The authors assess health-status outcomes of prophylaxis for Mycobacterium avium bacteremia in patients with advanced HIV disease. This report summaries the developmental work performed for trials, the field experience, and associated findings.

This report is part of the RAND draft series. The unrestricted draft was a product of RAND from 1993 to 2003 that represented preliminary or prepublication versions of other more formal RAND products for distribution to appropriate external audiences. The draft could be considered similar to an academic discussion paper. Although unrestricted drafts had been approved for circulation, they were not usually formally edited or peer reviewed.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.